Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia

References

• Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). American Psychiatric Association (2004).
   Google Scholar
• Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts”: what we know in 2008 Part 1: overview. Schizophr. Res.100(1–3), 4–19 (2008).
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc.86(8), 1646–1647 (1964).
   Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature346(6284), 561–564 (1990).
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature365(6441), 61–65 (1993).
   PubMed Web of Science ®Google Scholar
• Fride E, Foox A, Rosenberg E et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor. Eur. J. Pharmacol.461(1), 27–34 (2003).
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Cannabinoids. Curr. Drug Targets CNS Neurol. Disord.4(5), 507–530 (2005).
   PubMedGoogle Scholar
• Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science258(5090), 1946–1949 (1992).
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol.50(1), 83–90 (1995).
   PubMed Web of Science ®Google Scholar
• Krystal JH, D’Souza DC, Madonick S, Petrakis IL. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr. Res.35(Suppl.), S35–S49 (1999).
   PubMed Web of Science ®Google Scholar
• Blanchard JJ, Squires D, Henry T et al. Examining an affect regulation model of substance abuse in schizophrenia. The role of traits and coping. J. Nerv. Ment. Dis.187(2), 72–79 (1999).
   PubMed Web of Science ®Google Scholar
• Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res.75(1), 135–137 (2005).
   PubMed Web of Science ®Google Scholar
• McCleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr. Res.88(1–3), 187–191 (2006).
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Abi-Saab WM, Madonick S et al. Δ-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry57(6), 594–608 (2005).
   PubMed Web of Science ®Google Scholar
• Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr. Res.100(1–3), 242–251 (2008).
   PubMed Web of Science ®Google Scholar
• Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet2(8574), 1483–1486 (1987).
   PubMed Web of Science ®Google Scholar
• Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ325(7374), 1199 (2002).
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ325(7374), 1212–1213 (2002).
   PubMed Web of Science ®Google Scholar
• van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol.156(4), 319–327 (2002).
   PubMed Web of Science ®Google Scholar
• Viveros MP, Llorente R, Moreno E, Marco EM. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav. Pharmacol.16(5–6), 353–362 (2005).
   PubMed Web of Science ®Google Scholar
• Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br. J. Psychiatry187(6), 510–515 (2005).
   PubMed Web of Science ®Google Scholar
• Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry161(3), 501–506 (2004).
   PubMed Web of Science ®Google Scholar
• Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ330(7481), 11 (2005).
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol. Med.33(1), 15–21 (2003).
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction100(3), 354–366 (2005).
   PubMed Web of Science ®Google Scholar
• Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am. J. Med. Genet.114(8), 949–955 (2002).
   PubMed Web of Science ®Google Scholar
• Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction99(4), 425–430 (2004).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull.2(1), 19–76 (1976).
   PubMed Web of Science ®Google Scholar
• Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr. Bull.32(4), 637–643 (2006).
   PubMed Web of Science ®Google Scholar
• Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr. Bull.26(2), 441–449 (2000).
   PubMed Web of Science ®Google Scholar
• San L, Arranz B, Martinez-Raga J. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur. Addict. Res.13(4), 230–243 (2007).
   PubMed Web of Science ®Google Scholar
• Sundram S, Copolov D, Dean B. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch. Pharmacol.371(5), 428–433 (2005).
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res.107(3), 173–177 (2001).
   PubMed Web of Science ®Google Scholar
• Bowers MB, Kantrowitz JT. Elevated plasma dopamine metabolites in cannabis psychosis. Am. J. Psychiatry164(10), 1615–1616 (2007).
   PubMedGoogle Scholar
• Markianos M, Vakis A. Effects of acute cannabis use on urinary neurotransmitter metabolites and cyclic nucleotides in man. Drug. Alcohol Depend.14(2), 175–178 (1984).
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci.2(4), 358–363 (1999).
   PubMed Web of Science ®Google Scholar
• Cadogan AK, Alexander SP, Boyd EA, Kendall DA. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem.69(3), 1131–1137 (1997).
   PubMed Web of Science ®Google Scholar
• Gessa GL, Melis M, Muntoni AL, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol.341(1), 39–44 (1998).
   PubMed Web of Science ®Google Scholar
• Mailleux P, Vanderhaeghen JJ. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J. Neurochem.61(5), 1705–1712 (1993).
   PubMed Web of Science ®Google Scholar
• Bonnin A, de Miguel R, Castro JG, Ramos JA, Fernandez-Ruiz JJ. Effects of perinatal exposure to Δ9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J. Mol. Neurosci.7(4), 291–308 (1996).
   PubMedGoogle Scholar
• Dean B, Bradbury R, Copolov DL. Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biol. Psychiatry53(7), 585–592 (2003).
   PubMedGoogle Scholar
• Tzavara ET, Li DL, Moutsimilli L et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry59(6), 508–515 (2006).
   PubMedGoogle Scholar
• D’Souza DC, Perry E, MacDougall L et al. The psychotomimetic effects of intravenous Δ-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology29(8), 1558–1572 (2004).
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Ranganathan M, Braley G et al. Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology198(4), 587–603 (2008).
   Google Scholar
• D’Souza DC, Braley G, Blaise R et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl.) (2008) (Epub ahead of print).
   Google Scholar
• Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl.)188(4), 425–444 (2006).
   PubMed Web of Science ®Google Scholar
• Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol. Biochem. Behav.56(4), 803–807 (1997).
   PubMed Web of Science ®Google Scholar
• Schneider U, Leweke FM, Sternemann U, Weber MM, Emrich HM. Visual 3D illusion: a systems-theoretical approach to psychosis. Eur. Arch. Psychiatry Clin. Neurosci.246(5), 256–260 (1996).
   PubMed Web of Science ®Google Scholar
• Sternemann U, Schneider U, Leweke FM, Bevilacqua CM, Dietrich DE, Emrich HM. Pro-psychotic change of binocular depth inversion by sleep deprivation. Nervenarzt68(7), 593–596 (1997).
   PubMed Web of Science ®Google Scholar
• Schneider U, Leweke FM, Niemcyzk W, Sternemann U, Bevilacqua M, Emrich HM. Impaired binocular depth inversion in patients with alcohol withdrawal. J. Psychiatr. Res.30(6), 469–474 (1996).
   PubMedGoogle Scholar
• Koethe D, Gerth CW, Neatby MA et al. Disturbances of visual information processing in early states of psychosis and experimental Δ-9-tetrahydrocannabinol altered states of consciousness. Schizophr. Res.88(1–3), 142–150 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider U, Borsutzky M, Seifert J et al. Reduced binocular depth inversion in schizophrenic patients. Schizophr. Res.53(1–2), 101–108 (2002).
   PubMed Web of Science ®Google Scholar
• Semple DM, Ramsden F, McIntosh AM. Reduced binocular depth inversion in regular cannabis users. Pharmacol. Biochem. Behav.75(4), 789–793 (2003).
   PubMed Web of Science ®Google Scholar
• Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol. Biochem. Behav.66(1), 175–181 (2000).
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry56(10), 485–486 (1995).
   PubMed Web of Science ®Google Scholar
• Gray JA, Rawlins JNP. Comparator and buffer memory: an attempt to integrate two models of hippocamaö functions. In: The Hippocampus. Isaacson RL, Pribram KH (Eds), Plenum Press, NY, USA, 159–201 (1986).
   Google Scholar
• Frith CD, Done DJ. Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action. Psychol. Med.19(2), 359–363 (1989).
   PubMed Web of Science ®Google Scholar
• Malenka RC, Angel RW, Hampton B, Berger PA. Impaired central error-correcting behavior in schizophrenia. Arch. Gen. Psychiatry39(1), 101–107 (1982).
   PubMed Web of Science ®Google Scholar
• Emrich HM. A three-component-system hypothesis of psychosis. Impairment of binocular depth inversion as an indicator of a functional dysequilibrium. Br. J. Psychiatry Suppl.5, 37–39 (1989).
   PubMedGoogle Scholar
• Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport10(8), 1665–1669 (1999).
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Leweke FM, Gerth CW et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology29(11), 2108–2114 (2004).
   PubMed Web of Science ®Google Scholar
• Leweke FM, Giuffrida A, Koethe D et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res.94(1–3), 29–36 (2007).
   PubMed Web of Science ®Google Scholar
• De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis.2, 5 (2003).
   PubMedGoogle Scholar
• Yao JK, van Kammen DP, Reddy RD et al. Elevated endocannabinoids in plasma from patients with schizophrenia. Biol. Psychiatry51, 64S–65S (2002).
   Google Scholar
• Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience48(3), 655–668 (1992).
   PubMed Web of Science ®Google Scholar
• Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience103(1), 9–15 (2001).
   PubMed Web of Science ®Google Scholar
• Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry28(2), 355–360 (2004).
   PubMed Web of Science ®Google Scholar
• Koethe D, Llenos IC, Dulay JR et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J. Neural. Transm.114(8), 1055–1063 (2007).
   PubMed Web of Science ®Google Scholar
• Newell KA, Zavitsanou K, Jew SK, Huang XF. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry31(1), 225–233 (2007).
   PubMed Web of Science ®Google Scholar
• Newell KA, Zavitsanou K, Huang XF. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. Neuroreport16(12), 1363–1367 (2005).
   PubMedGoogle Scholar
• Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res.172(4), 556–560 (2006).
   PubMed Web of Science ®Google Scholar
• Berding G, Schneider U, Gielow P et al. Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient. Psychiatry Res.147(2–3), 249–256 (2006).
   PubMedGoogle Scholar
• Chua SE, Cheung C, Cheung V et al. Cerebral grey, white matter and CSF in never-medicated, first-episode schizophrenia. Schizophr. Res.89(1–3), 12–21 (2007).
   PubMed Web of Science ®Google Scholar
• Cahn W, van Haren NE, Hulshoff Pol HE et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br. J. Psychiatry189(4), 381–382 (2006).
   PubMed Web of Science ®Google Scholar
• Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend.77(1), 23–30 (2005).
   PubMed Web of Science ®Google Scholar
• Block RI, O’Leary DS, Ehrhardt JC et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport11(3), 491–496 (2000).
   PubMed Web of Science ®Google Scholar
• Cahn W, Hulshoff Pol HE, Caspers E, van Haren NE, Schnack HG, Kahn RS. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr. Res.67(2–3), 305–307 (2004).
   PubMedGoogle Scholar
• Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia – a region of interest, voxel based morphometric study. Schizophr. Res.99(1–3), 1–6 (2008).
   PubMed Web of Science ®Google Scholar
• Szeszko PR, Robinson DG, Sevy S et al. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br. J. Psychiatry190(3), 230–236 (2007).
   PubMed Web of Science ®Google Scholar
• Rais M, Cahn W, Van Haren N et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry165(4), 490–496 (2008).
   PubMed Web of Science ®Google Scholar
• Broome MR, Woolley JB, Tabraham P et al. What causes the onset of psychosis? Schizophr. Res.79(1), 23–34 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis CM, Levinson DF, Wise LH et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am. J. Hum. Genet.73(1), 34–48 (2003).
   PubMed Web of Science ®Google Scholar
• Ujike H, Takaki M, Nakata K et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry7(5), 515–518 (2002).
   PubMed Web of Science ®Google Scholar
• Gadzicki D, Müller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol. Cell Probes13(4), 321–323 (1999).
   PubMed Web of Science ®Google Scholar
• Martínez-Gras I, Hoenicka J, Ponce G et al. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur. Arch. Psychiatry Clin. Neurosci.256(7), 437–441 (2006).
   PubMed Web of Science ®Google Scholar
• Leroy S, Griffon N, Bourdel MC, Olié JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet.105(8), 749–752 (2001).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr. Genet.10(3), 149–151 (2000).
   PubMed Web of Science ®Google Scholar
• Zammit S, Spurlock G, Williams H et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry191(5), 402–407 (2007).
   PubMed Web of Science ®Google Scholar
• Henquet C, Rosa A, Krabbendam L et al. An experimental study of catechol-O-methyltransferase Val158Met moderation of Δ-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology31(12), 2748–2757 (2006).
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry57(10), 1117–1127 (2005).
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by Δ 9-THC in normal subjects. Psychopharmacology (Berl.)76(3), 245–250 (1982).
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl.)104(2), 260–264 (1991).
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry56(10), 485–486 (1995).
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Hallak JE, Dursun SM et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol.20(5), 683–686 (2006).
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Guimarães FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz. J. Med. Biol. Res.26(2), 213–217 (1993).
   PubMed Web of Science ®Google Scholar
• Consroe P, Laguna J, Allender J et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav.40(3), 701–708 (1991).
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem. Phys. Lipids121(1–2), 35–43 (2002).
   PubMed Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol.134(4), 845–852 (2001).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry161(6), 975–984 (2004).
   PubMed Web of Science ®Google Scholar
• Madsen MV, Peacock L, Werge T, Andersen MB. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on dHamphetamine-induced behaviours in Cebus monkeys. J. Psychopharmacol.20(5), 622–628 (2006).
   PubMedGoogle Scholar
• Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry192, 306–307 (2008).
   PubMed Web of Science ®Google Scholar